Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain

Objective The Centers for Disease Control and Prevention (CDC) and many state governments have issued guidelines for opioid prescribing for the treatment of chronic noncancer‐associated pain. We sought to decrease practice variation and increase compliance with these guidelines in a tertiary academi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis care & research (2010) 2021-10, Vol.73 (10), p.1425-1429
Hauptverfasser: Wang, Eric J., Helgesen, Rebecca, Johr, Chadwick R., Lacko, Hannah S., Ashburn, Michael A., Merkel, Peter A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective The Centers for Disease Control and Prevention (CDC) and many state governments have issued guidelines for opioid prescribing for the treatment of chronic noncancer‐associated pain. We sought to decrease practice variation and increase compliance with these guidelines in a tertiary academic rheumatology practice by developing an interdisciplinary opioid working group and using electronic health record (EHR)–integrated data feedback. Methods Division leadership and providers established shared goals at interdisciplinary meetings involving rheumatology, pain medicine, nursing, and pharmacy. Interventions included educational sessions on opioid prescribing guidelines and the sharing of individual de‐identified prescribing patterns. An opioid dashboard page within the EHR allowed every provider to see individualized and division‐wide data that tracked process measures based on CDC and state‐specific guidelines. Baseline data from June to August 2017 were compared with monthly data through December 2018. Results At baseline, 40% of patients had an active opioid agreement (a Pennsylvania guideline and a New Jersey law), 25% had a urine drug screen result within 12 months of their most recent opioid prescription, and 24% had a concurrent benzodiazepine prescription. After 16 months, these percentages improved to 88%, 66%, and 16%, respectively. The average number of opioid tablets prescribed per month decreased from 59,733 to 48,966 (–18%; P = 0.02). Conclusion Shared goals developed through interdisciplinary input and readily accessible data feedback can markedly increase provider compliance with national and state‐specific guidelines for opioid prescribing for the treatment of chronic noncancer‐associated pain in rheumatology.
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.24354